CD8A and neoplasm: Studies show that CAFs lead to a decrease in the number of CD8+ T cells with critical anti-tumor function in the TME [97–99], reduced PD-L1 expression [98], and render tumors resistant to immune checkpoint blockade (ICB) therapy [99].